Drug Names Molecular Clonal Tracking Method Captures Lung Cancer Treatment Response, Resistance Features Using a single-cell sequencing and clonal fitness mapping method, researchers compared EGFR-mutant lung cancer cell responses to EGFR inhibition or targeted protein degradation. Illumina, Merck Partner to Advance Homologous Recombination Deficiency CDx, Research Assay Under the terms of the deal, Illumina will develop a new HRD CDx for the EU and UK markets and a research-use only HRD assay that will be add-on content for its TSO 500 panel. Amoy Diagnostics CDx Gets Japanese Approval to ID NSCLC Patients Eligible for Tepmetko The Japanese Ministry of Health, Labor, and Welfare has approved AmoyDx's PLC Panel for use in identifying NSCLC patients with MET exon 14 skipping alterations. Sequencing-Based Assessment of CYP2D6 Could Improve Prediction of Drug Response Premium Researchers have developed a computational method that considers uncommon CYP2D6 variants to assess patient-specific metabolism of tamoxifen and other drugs. FDA Approves Foundation Medicine's Liquid Biopsy Test as CDx for Novartis' Tabrecta in NSCLC The blood-based test is the second Foundation Medicine assay approved to ID patients eligible for the drug due to mutations leading to MET exon 14 skipping. Jul 1, 2021 FDA Approves FoundationOne CDx for Takeda's ALK-Inhibitor Jun 14, 2021 Genecast to Evaluate Liquid Biopsy EGFR Mutation Test in Early-Stage Non-Small Cell Lung Cancer Jun 7, 2021 Lynparza Benefit in Early BRCA-Mutated Breast Cancer Reignites Universal Genetic Testing Discussion Premium May 26, 2021 23andMe Begins Reporting PGx Variants With Drug Info Under Recent FDA Clearance Premium May 7, 2021 Breast Cancer Immunotherapy Response Markers Emerge From Single-Cell Sequencing Study Apr 12, 2021 Oncocyte AACR Data Expands Potential Applications for Immunotherapy Response Predictor Apr 6, 2021 Uterine Leiomyosarcoma Sequences Point to Potentially Targetable Somatic Mutations Mar 18, 2021 Oncocyte Details New Expansions Plans With Growing Portfolio of Acquired Tests Premium Mar 17, 2021 Meta-Analysis Supports Pharmacogenomic Testing Prior to Anti-Platelet Therapy Mar 16, 2021 Cofactor Genomics Cements Clinical Diagnostic Plans as Immunotherapy Prediction Data Builds Premium Feb 26, 2021 Natera Launches Tumor Genomic Profiling Assay, Expects Reproductive Health to Break Even This Year Premium Feb 18, 2021 MSK Study Underscores Need to Validate Cancer-Specific Tumor Mutational Burden Cutoffs Premium Feb 16, 2021 Circulating Tumor DNA Provides Prognostic Clues in Advanced BRAF-Mutated Melanoma Cases Feb 8, 2021 Sophia Genetics, Spanish Lung Cancer Group Team up to Predict Lung Cancer Treatment Response Jan 28, 2021 OmniSeq, UPMC Partner on Immunotherapy Trial Matching for Head and Neck Cancer Jan 26, 2021 Researchers ID Four Small Cell Lung Cancer Subtypes, Suggest Future Treatment Implications Premium Jan 20, 2021 Biotheranostics' Breast Cancer Index Included in Latest NCCN Guidelines Dec 23, 2020 Amoy Diagnostics, Merck KGaA Partner for Lung Cancer Companion Diagnostic Development in China Dec 10, 2020 Tempus Raises $200M in Series G2, Inks Oncology Testing Collaboration With Bayer Nov 19, 2020 Exceptional Responders Cancer Study Points to Possible Treatment Targets Premium Load More Breaking News Vibrent Health, University of Maryland Medicine Partner for Population Health Initiative Polygenic Risk Scores for Breast, Prostate Cancer Adaptable for Cross-Ancestry Use, Study Shows Molecular Clonal Tracking Method Captures Lung Cancer Treatment Response, Resistance Features Oxford Nanopore Technologies to Raise £300M in IPO, Including £150M Investment by Oracle Thermo Fisher Scientific Receives CE Mark for TaqPath COVID-19 RNase P 2.0 Testing Kit Castle Biosciences Receives New York State Approval for DecisionDx DiffDx-Melanoma Test The Scan Tennessee's COVID-19 Sequencing The Tennessean reports that a state lab there can now run its own genome sequencing analyses of SARS-CoV-2 samples. Sanction Violation Charges A former professor has been charged with exporting genetic sequencing equipment to Iran in violation of US sanctions, the Miami Herald reports. Prenetics to Go Public Through SPAC Prenetics, a Hong Kong-based genomic and diagnostic company, is going public through a SPAC merger, according to 360Dx. Nature Papers Examine Genomes of Centenarians, Transcription-Coupled DNA Repair In Nature this week: analysis of centenarian genomes uncovers longevity-linked variants, and more.